GVR Report cover CRISPR And Cas Genes Market Size, Share & Trends Report

CRISPR And Cas Genes Market Size, Share & Trends Analysis Report By End-use (CROs, Biotech & Pharma Companies), By Application (Biomedical, Agriculture), By Product & Service, By Region, And Segment Forecasts, 2022 - 2030

  • Report ID: GVR-1-68038-375-1
  • Number of Pages: 170
  • Format: Electronic (PDF)
  • Historical Range: 2018 - 2020
  • Industry: Healthcare

Report Overview

The global CRISPR and Cas genes market size was valued at USD 2.05 billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 17.9% from 2022 to 2030. Recent advancements in biotechnological research have enabled CRISPR & Cas gene systems to find widespread applications that directly or indirectly aid human health. For example, somatic gene editing, which involves engineering an individual’s DNA, has been used to treat diseases like HIV, sickle-cell disease, and transthyretin amyloidosis. The technique is anticipated to be part of novel therapeutic options for different types of cancers. The technological advancements in CRISPR & Cas gene systems have contemporarily revolutionized the area of cancer research and therapeutics.

Japan CRISPR & Cas genes market size, by product & service, 2020 - 2030 (USD Million)

Moreover, the COVID-19 pandemic has boosted the usage of CRISPR & Cas gene technology and has been widely used in nucleic acid detection due to its reliability and sensitivity. Since the advent of CRISPR as a tool for DNA editing, it is increasingly being adopted by key biotechnology and pharmaceutical companies for the development of drugs and therapies. For instance, in August 2022, iNtRON Biotechnology announced the development of a customized CRISPR/Cas system for the genetic modification of bacteria and bacteriophage. The CRISPR technology improves the therapeutic efficacy of modified T-cells for the treatment of various malignancies. In addition, the development of Chimeric Antigen Receptor T (CAR-T) cells is strongly related to cancer treatment.

In May 2022, Caribou Biosciences, Inc. presented data on the mechanism underlying the potential of the chRDNA genome-editing technology in primary human T cells. It provides a reproducible and robust technique to boost the specificity of genome editing, and it improves the efficacy of allogeneic cell therapies. These developments are anticipated to drive the growth of the industry in the coming years. Innovative technologies, such as karyotyping, neonatal screening, viral screening, and others, have boosted the demand for gene editing techniques like CRISPR & Cas gene technology. Moreover, the use of CRISPR & Cas gene technology to enhance agricultural production through innovative breeding strategies have increased the adoption of these technologies in the biotechnology industry.

Product & Service Insights

Based on product & service, the global industry has been further categorized into products and services. The product segment dominated the global industry in 2021 and accounted for the highest share of more than 79.00% of the overall revenue. Several cutting-edge technologies, such as CRISPR gene editing kits, have been developed to meet the growing demands for genome editing solutions. The maximum revenue share can be attributed to the availability of enhanced individual products that can be used to achieve a variety of goals, including simple gene knockouts, selective genome cleavage, reduced off-target cutting, genome engineering, and higher specificity.

Furthermore, increased investments in gene editing-based R&D, along with the introduction of several applications, are anticipated to drive the growth of the service segment during the forecast period. For instance, in July 2022, a U.K. charity (The British Heart Foundation) provided USD 36 million to an international team to develop innovative gene-editing treatments for inherited heart diseases. Recent gene editing techniques, particularly CRISPR technology, have offered several opportunities to combat cardiovascular diseases.

Application Insights

On the basis of applications, the global industry has been further categorized into biomedical and agricultural. The biomedical application segment dominated the global industry in 2021 and accounted for the largest share of more than 92.55% of the total revenue. The increasing utilization of CRISPR gene-editing technologies in a number of biological science fields has significantly contributed to the segment’s high revenue share. The effectiveness and specificity of this technology have been enhanced by better delivery methods and the introduction of nanocarriers. The number of studies and publications that use this method to modify the genomes of human somatic cells and induced pluripotent stem cells has significantly increased.

In addition, some companies provide commercial kits and services to help researchers who are working in this domain. On the other hand, the agriculture application segment is anticipated to register the fastest growth rate during the forecast period. Improvements in agricultural production through the incorporation of innovative breeding technology have increased access to nutrition-rich foods globally. For instance, in June 2019, researchers at the Cold Spring Harbor Laboratory implemented CRISPR/Cas9 technology to induce mutations in the flowering suppressor of tomatoes, which resulted in rapid flowering and improved compact growth of tomatoes, finally an early yield.

End-use Insights

On the basis of end-uses, the global industry has been further categorized into biotechnology & pharmaceutical companies, academics & government research institutes, and Contract Research Organizations (CROs). The biotechnology and pharmaceutical companies end-use segment dominated the global industry in 2021 and accounted for the maximum share of more than 49.20% of the overall revenue. Pharmaceutical companies are utilizing these technologies more frequently to quickly identify and validate new therapeutic targets and to produce better biological models for human diseases in less time.

Global CRISPR & Cas genes market share, by end-use, 2021 (%)

The segment is also anticipated to be further driven by the rising number of biotechnology companies using gene modification for both research and commercial purposes. In addition, there is a huge demand for CRISPR-based gene-editing methods for the creation of innovative medicines for cell and gene therapies. CRISPR’s core architecture has been modified by extending its reach into the epigenome and granting control over an epigenetic inheritance. For instance, in April 2021, researchers from the Massachusetts Institute of Technology and the University of California created a CRISPR on-off switch to regulate gene expression.

Regional Insights

On the basis of geographies, the global industry has been further categorized into North America, Europe, Latin America, Middle East & Africa, and Asia Pacific. The North American region dominated the global industry in 2021 and accounted for the maximum share of more than 38.40% of the overall revenue. The growing biopharmaceutical R&D as well as the involvement of several pharmaceutical corporations in the creation of novel therapeutics has contributed to the region’s growth. For instance, in May 2020, Merck KGaA received U.S. approval for two of its CRISPR Cas9-driven gene-editing patents.

CRISPR And Cas Genes Market Trends by Region

Asia Pacific, on the other hand, is anticipated to witness the fastest growth rate during the forecast period. The increasing government investment in R&D to develop novel treatments is aiding in the market expansion in Japan and China. For instance, in March 2021, Japanese biotech company Setsuro Tech received a patent for CRISPR-Cas9 technology from Dublin-based ERS Genomics. The company is creating animal and cell models using these advanced technologies. Such initiatives are predicted to enhance CRISPR technology adoption in the region, further contributing to revenue generation.

Key Companies & Market Share Insights

Strategic initiatives, product developments, and regional expansions are key strategies that contribute to industry development. For instance, in November 2021, GenScript launched a double-stranded DNA service to expand its cell and gene therapy product portfolio using CRISPR & Cas gene technology. In March 2021, Integrated DNA Technologies launched AmpSeq CRISPR Analysis System, which offers end-to-end solutions for quantifying the full array of on- and off-target genome editing results in CRISPR research projects. Some of the key players in the global CRISPR and Cas genes market include:

  • AstraZeneca plc

  • Addgene

  • Caribou Biosciences, Inc.

  • Cellectis, CRISPR Therapeutics

  • Editas Medicine, Inc.

  • eGenesis

  • F. Hoffmann-La Roche Ltd.

  • Horizon Discovery Group plc

  • GenScript

  • Danaher Corp.

  • Intellia Therapeutics, Inc.

  • Lonza

  • Merck KGaA

  • Intellia Therapeutics, Inc.

  • Takara Bio Inc.

  • Thermo Fisher Scientific, Inc.

  • Synthego

  • Mammoth Biosciences

  • Inscripta, Inc.

  • Cibus

  • Beam Therapeutics


  • Vertex Pharmaceuticals Inc.

  • Hera BioLabs

  • OriGene Technologies, Inc.

  • Recombinetics, Inc.

CRISPR And Cas Genes Market Report Scope

Report Attribute


Market size value in 2022

USD 2.57 billion

Revenue forecast in 2030

USD 9.6 billion

Growth rate

CAGR of 17.9% from 2022 to 2030

Base year for estimation


Historical data

2018 - 2020

Forecast period

2022 - 2030

Quantitative units

Revenue in USD million/billion and CAGR from 2022 to 2030

Report coverage

Revenue forecast, company ranking, competitive landscape, growth factors, and trends

Segments covered

Product & service, application, end-use, region

Regional scope

North America; Europe; Asia Pacific; Latin America; Middle East & Africa

Country scope

U.S.; Canada; Germany; France; Italy; Spain; U.K.; China; Japan; South Korea; India; Brazil; Mexico; South Africa; Saudi Arabia

Key companies profiled

AstraZeneca; Addgene; Caribou Biosciences, Inc.; Cellectis; CRISPR Therapeutics; Editas Medicine, Inc.; eGenesis; F. Hoffmann-La Roche Ltd.; Horizon Discovery Group plc; GenScript; Danaher Corp.; Intellia Therapeutics, Inc.; Lonza; Merck KGaA; Intellia Therapeutics, Inc.; Takara Bio Inc.; Thermo Fisher Scientific, Inc.; Synthego; Mammoth Biosciences; Inscripta, Inc.; Cibus; Beam Therapeutics; PLANTeDIT; Vertex Pharmaceuticals Incorporated; Hera BioLabs; OriGene Technologies, Inc.; Recombinetics, Inc.

Customization scope

Free report customization (equivalent up to 8 analyst’s working days) with purchase. Addition or alteration to country, regional & segment scope.

Pricing and purchase options

Avail customized purchase options to meet your exact research needs. Explore purchase options


Global CRISPR And Cas Genes Market Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For the purpose of this study, Grand View Research has segmented the global CRISPR and Cas genes market report on the basis of product & service, application, end-use, and region:

Global CRISPR And Cas Genes Market Segmentation

  • Product & Service Outlook (Revenue, USD Million, 2018 - 2030)

    • By Product

      • Kits & Enzymes

        • Vector-based Cas

        • DNA-free Cas

      • Libraries

      • Design Tool

      • Antibodies

      • Others

    • By Service

      • Cell Line Engineering

      • gRNA Design

      • Microbial Gene Editing

      • DNA Synthesis

  • Application Outlook (Revenue, USD Million, 2018 - 2030)

    • Biomedical

      • Genome Engineering

      • Disease Model Studies

      • Functional Genomics

      • Epigenetics

      • Others

    • Agricultural

  • End-use Outlook (Revenue, USD Million, 2018 - 2030)

    • Biotechnology & Pharmaceutical Companies

    • Academics & Government Research Institutes

    • Contract Research Organizations (CROs)

  • Regional Outlook (Revenue, USD Million, 2018 - 2030)

    • North America

      • U.S.

      • Canada

    • Europe

      • Germany

      • France

      • Italy

      • Spain

      • U.K.

    • Asia Pacific

      • China

      • Japan

      • India

      • South Korea

    • Latin America

      • Brazil

      • Mexico

    • Middle East & Africa

      • South Africa

      • Saudi Arabia

Frequently Asked Questions About This Report

gvr icn


gvr icn

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

gvr icn


We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

esomar icon

ESOMAR certified & member

D&B icon

Leading SME award by D&B

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.

great place to work icon